Hyderabad: Almost 30% of individuals lose their vaccine immunity after six months, a study was conducted to understand the longevity of vaccine immunity in the Indian population in connection with the level of antibodies.
This study was conducted by AIG Hospital along with the Asian Healthcare Foundation in 1,636 health workers entirely vaccinated with three Covid-19 vaccines currently being managed in the country.
Of the 1,636 participants in this study, 93% (1519 individuals) have received a covishield, 6.2% (102) gets covaxin and less than 1% (13) has been managed by sputnik jab.
The results of the study were uploaded on Wednesday on pre-print server research, which was a prefrint platform where research papers were uploaded before peer-reviewed.
The researchers involved in this study measured anti-S1 antibodies and anti-S2 IgG to SARS-COV-2 in 1,636 of these individuals.
Those who have an antibody level of less than 15 au / mL are considered negative antibodies, which means they do not develop protective immunity against the virus.
Furthermore, it is estimated that the 100 AU / ML antibody level is the minimum level for protection against viruses, which means each individual with an uninfected level of AU / ML antibodies.
“Our results are equivalent to other global studies where we find that nearly 30% of individuals have an antibody level below the level of protective immunity of 100 au / ml after six months.
These individuals are largely above 40 years with co-morbidity such as hypertension And diabetes.
Of the total, 6% did not develop immune protection at all, “said Dr.
D Nageshwar Reddy, Chair, AIG Hospital, who is one of the researchers.
The researchers show that these results clearly show that with age, direct congestion is proportional which means that younger people have a more sustainable level of antibodies than the elderly population.
With those above 40 years with co-morbidities such as hypertension and diabetes show far less antibody responses after six months to be fully vaccinated, individuals from both sexes over 40 years old and suffer from co-morbidity such as hypertension and diabetes may be at risk The infection height and therefore must be prioritized for a booster dose after six months.
“At present, the nine-month gap for a profitable 70% prevention dose of the population can maintain enough antibody levels outside six months.
However, given the scale of our country, 30% of people, especially those who have co-morbid conditions such as hypertension, diabetes, which are More vulnerable to developing infection after six months to be fully vaccinated must also be considered for preventive doses, “Dr.
Reddy added.
Show that the country currently sees a surge in infection, he said: “Fortunately, the severity of this disease is mild because many factors include the effect of vaccination, the intrinsic character of the variant itself, and natural immunity among the population.
However, we need to design a strategy that can ensure minimal deployment and protect as many people as possible.
This study aims to understand the effectiveness of the current vaccine during the long term and see if there are certain population demographics that need the earliest booster, “Reddy said.